High-risk merchant account for SARMs operators
3-minute scan
- SARMs merchant account pool is smaller than peptide; regulatory heat is higher.
- Acquirers focus heavily on SKU list — certain compounds trigger automatic decline.
- Research-chemical disclaimer + operational compliance materially improve approval odds.
On this page
SARMs merchant accounts are harder to secure in 2026 than peptide accounts. FDA has taken more public enforcement action on specific compounds, and acquirer underwriting reflects it. Certain SARMs SKUs (MK-677, RAD-140 in some cases) trigger automatic decline. The remaining pool is narrower than 2-3 years ago, but viable operators still exist.
Active SARMs-approving acquirers
High-risk ISOs with SARMs placements
- EasyPayDirect — most consistent SARMs placements. Rate 4.0-4.5% effective, 10-15% reserve, 180 days.
- Durango Merchant Services — places SARMs through specialty acquirers.
- Corepay — SARMs with heavy SKU review.
- PayKings — accepts SARMs but tight marketing-copy review.
- Soar Payments — newer SARMs placements; verify active.
- High Risk Pay — broader high-risk book.
Offshore
- Emerchantpay (EU) — US SARMs merchants with compliance documentation.
- Paynetics (EU) — high-risk specialty.
SKU review — the primary gate
Commonly approved SARMs
- Ostarine (MK-2866) — most commonly approved
- Cardarine (GW-501516) — sometimes approved
- S4 (Andarine) — sometimes approved
- SR-9009 — case-by-case
Enhanced review / often declined
- RAD-140 (Testolone)
- LGD-4033 (Ligandrol)
- MK-677 (Ibutamoren) — frequently declined post-2024
- YK-11
Typically declined
- Tesofensine
- Stenabolic combined with peptide products
- Pro-hormones categorized as SARMs
- Combination products blurring research-chemical line
Research-chemical positioning
All SARMs-approved acquirers require "for research purposes only" labeling and disclaimer. This isn't just legal cover — it's underwriting requirement:
- Product labels include "research use only"
- Checkout disclaimer acknowledgment (customer checks box)
- Timestamp + IP captured at acknowledgment
- Website disclaimer prominent
- No human-consumption imagery in marketing
Operators who don't maintain research-chemical framing consistently get closed fast.
Marketing copy review
Acquirer audit checks site copy for:
- No "best for bodybuilding" or consumption framing
- No before/after human transformation photos
- No specific dosing guidance
- No therapeutic benefit claims
- No FDA-regulated claim language
One aggressive copy block can trigger enhanced review or closure.
Rate and reserve reality
- Effective rate: 4.0-5.5% all-in
- Rolling reserve: 10-20%, 180-day hold
- Upfront reserve: $10-25k sometimes required
- Volume cap: $50-200k/month initial
- Chargeback pause trigger: 0.7% monthly
- Contract term: 2-3 year with $250-500 ETF
Freight-forwarder and international risk
SARMs fraudsters resell overseas aggressively. Freight-forwarder addresses (StackRY, Reship, MyUS) are fraud indicators. Acquirer may require:
- Freight-forwarder address blocking
- International shipping restrictions
- Enhanced 3DS on cross-border transactions
- AVS match strict enforcement
Multi-brand SARMs operator structure
Running 3+ SARMs brands typically benefits from parent-merchant consolidation:
- One underwriting relationship vs N
- Consolidated reserve (usually 2-4 points lower percentage)
- Shared fraud intelligence across brands
- Unified representment team
- Brand-preserved dynamic descriptors
Compliance documentation package
- Product label with research-chemical disclaimer
- COA for each SKU
- Supplier documentation
- Manufacturing compliance
- Marketing copy samples
- Age-verification flow screenshots
- State restriction enforcement documentation
Common pitfalls at application
- Site copy that slipped into human-consumption framing
- Missing research-chemical disclaimer on checkout
- SKU list including compounds not accepted by current acquirer
- Processing history from previous closed account not disclosed
- Bank statements showing commingling with non-SARMs business
What to check before signing
- Which specific acquirer backs the ISO for SARMs
- Exact SKU list approved (ask in writing)
- Chargeback pause threshold
- Reserve release schedule
- Contract term + ETF
- Volume cap + lift conditions
- Research-chemical framework guidance
Alternative rails for SARMs
- Crypto (USDC) — 10-15% volume capture
- ACH — 20-30% capture
- Wire — wholesale / bulk orders
- eCheck — some legacy customers
What not to do
- Don't apply to Stripe / Square. Declined fast + noted.
- Don't underdescribe SKU list. Audit discovers and closes.
- Don't skip freight-forwarder blocking. Fraud ring detects unblocked operators.
- Don't market human use. Closes the account + adds FDA risk.
- Don't sign 3-year contracts without ETF negotiation.
What to do next
Complete documentation. Apply to 2-3 SARMs-capable ISOs in parallel. Compare actual contracts. Pick on rate + reserve + approved SKU list scope.
Multi-brand: parent-account structure. Our application covers SARMs portfolio assessments.
FAQ
Can I sell SARMs online legally?
Selling SARMs as research chemicals with appropriate labeling is not uniformly illegal, but FDA has taken action against specific operators and compounds. Consult legal counsel; this is operational guidance only.
Why is RAD-140 harder to process than Ostarine?
RAD-140 has been targeted more by FDA enforcement and acquirer compliance teams. SKU-specific review reflects regulatory attention.
Can I carry all SARMs on one merchant account?
Not typically. Most acquirers approve a subset of SARMs; restricted compounds go on alternative rails or are excluded.
How long does SARMs underwriting take?
10-21 business days with complete documentation. Edge-case SKUs extend this.
What if I was closed on a prior SARMs account?
Disclose on new application. Non-disclosure discovered during underwriting can trigger MATCH entry.
Do I need AKA or another certification?
Not for SARMs (no industry body equivalent to AKA for kratom). Documented compliance program matters more.